Tags

Type your tag names separated by a space and hit enter

Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.
Diabet Med 1999; 16(12):1040-3DM

Abstract

AIMS

To evaluate the efficacy and safety of short-term oral treatment with the antioxidant thioctic acid (TA) on neuropathic symptoms and deficits in patients with Type 2 diabetes mellitus with symptomatic polyneuropathy.

METHODS

Patients were randomly assigned to oral treatment with 600 mg of TA t.i.d. (n = 12) or placebo (n = 12) for 3 weeks. Neuropathic symptoms (pain, burning, paraesthesiae, and numbness) in the feet were scored at weekly intervals and summarized as a Total Symptom Score (TSS). The Hamburg Pain Adjective List (HPAL) and the Neuropathy Disability Score (NDS) were assessed at baseline and day 19.

RESULTS

At baseline the TSS, HPAL, and NDS were not significantly different between the groups. The TSS in the foot decreased from baseline to day 19 by -3.75 +/- 1.88 points (-47%) in the TA group and by -1.94 +/- 1.50 points (-24%) in the placebo group (P= 0.021 for TA vs. placebo). The total HPAL score decreased from baseline to day 19 by -2.20 +/- 1.65 points (-60%) in the TA group and by -0.96 +/- 1.32 points (-29%) in the placebo group (P = 0.072 for TA vs. placebo). The NDS decreased by -0.27 +/- 0.47 points in the TA group, whereas it slightly increased by +0.18 +/- 0.4 points in the placebo group (P = 0.025 for TA vs. placebo). No differences between the groups were noted regarding the rates of adverse events.

CONCLUSIONS

These preliminary findings indicate that oral treatment with 600 mg of TA t.i.d. for 3 weeks may improve symptoms and deficits resulting from polyneuropathy in Type 2 diabetic patients, without causing significant adverse reactions.

Authors+Show Affiliations

Deutsches Diabetes-Forschungsinstitut an der Heinrich-Heine-Universität, Düsseldorf, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10656234

Citation

Ruhnau, K J., et al. "Effects of 3-week Oral Treatment With the Antioxidant Thioctic Acid (alpha-lipoic Acid) in Symptomatic Diabetic Polyneuropathy." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 16, no. 12, 1999, pp. 1040-3.
Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16(12):1040-3.
Ruhnau, K. J., Meissner, H. P., Finn, J. R., Reljanovic, M., Lobisch, M., Schütte, K., ... Ziegler, D. (1999). Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabetic Medicine : a Journal of the British Diabetic Association, 16(12), pp. 1040-3.
Ruhnau KJ, et al. Effects of 3-week Oral Treatment With the Antioxidant Thioctic Acid (alpha-lipoic Acid) in Symptomatic Diabetic Polyneuropathy. Diabet Med. 1999;16(12):1040-3. PubMed PMID: 10656234.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. AU - Ruhnau,K J, AU - Meissner,H P, AU - Finn,J R, AU - Reljanovic,M, AU - Lobisch,M, AU - Schütte,K, AU - Nehrdich,D, AU - Tritschler,H J, AU - Mehnert,H, AU - Ziegler,D, PY - 2000/2/3/pubmed PY - 2000/2/19/medline PY - 2000/2/3/entrez SP - 1040 EP - 3 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet. Med. VL - 16 IS - 12 N2 - AIMS: To evaluate the efficacy and safety of short-term oral treatment with the antioxidant thioctic acid (TA) on neuropathic symptoms and deficits in patients with Type 2 diabetes mellitus with symptomatic polyneuropathy. METHODS: Patients were randomly assigned to oral treatment with 600 mg of TA t.i.d. (n = 12) or placebo (n = 12) for 3 weeks. Neuropathic symptoms (pain, burning, paraesthesiae, and numbness) in the feet were scored at weekly intervals and summarized as a Total Symptom Score (TSS). The Hamburg Pain Adjective List (HPAL) and the Neuropathy Disability Score (NDS) were assessed at baseline and day 19. RESULTS: At baseline the TSS, HPAL, and NDS were not significantly different between the groups. The TSS in the foot decreased from baseline to day 19 by -3.75 +/- 1.88 points (-47%) in the TA group and by -1.94 +/- 1.50 points (-24%) in the placebo group (P= 0.021 for TA vs. placebo). The total HPAL score decreased from baseline to day 19 by -2.20 +/- 1.65 points (-60%) in the TA group and by -0.96 +/- 1.32 points (-29%) in the placebo group (P = 0.072 for TA vs. placebo). The NDS decreased by -0.27 +/- 0.47 points in the TA group, whereas it slightly increased by +0.18 +/- 0.4 points in the placebo group (P = 0.025 for TA vs. placebo). No differences between the groups were noted regarding the rates of adverse events. CONCLUSIONS: These preliminary findings indicate that oral treatment with 600 mg of TA t.i.d. for 3 weeks may improve symptoms and deficits resulting from polyneuropathy in Type 2 diabetic patients, without causing significant adverse reactions. SN - 0742-3071 UR - https://www.unboundmedicine.com/medline/citation/10656234/Effects_of_3_week_oral_treatment_with_the_antioxidant_thioctic_acid__alpha_lipoic_acid__in_symptomatic_diabetic_polyneuropathy_ L2 - https://ClinicalTrials.gov/search/term=10656234 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -